BACKGROUND/AIMS: @entity1534 ( @entity1534 ) infection is one of the most common @entity344 . An increasing number of @entity1 undergo different treatment options. Unfortunately, @entity1534 therapy may be troublesome for @entity137 and inefficacious for resistance to antibiotics. METHODOLOGY: One hundred and ninety-three (193) @entity1534 -positive @entity1 were randomly assigned to one of the following 7-day treatments: Group A (N = 64): @entity115 , @entity4581 and @entity7619 ; Group B (N = 64): @entity7015 , @entity4581 and @entity11450 ; Group C (N = 65): @entity7015 , @entity4581 and @entity7619 Eradication was assessed by @entity7352 -Urea Breath Test 6-8 weeks after the end of the therapy. Not-eradicated @entity1 underwent a second cycle with @entity7015 , @entity803 , @entity1535 and @entity7619 . All @entity1 were asked to complete a validated questionnaire regarding presence and intensity of @entity137 . RESULTS: One hundred and eighty-eight out of the 193 @entity1534 -positive @entity1 (96%) completed therapy. No significant difference in eradication rates was observed among the three groups both in intention to treat analysis and in per protocol analysis. No significant difference in incidence of side effects occurred among groups after the first-line regimens: 48% in group A, 44% in group B and 46% in group C. Twenty-two out of the 193 enrolled subjects (11%) were not eradicated after the first-line therapy. Among them, 86% were successfully eradicated by the @entity7015 , @entity803 , @entity1535 and @entity7619 therapy. Moreover, during quadruple therapy, a higher prevalence and intensity of side effects than in each one of the groups submitted to the first-line triple therapy was observed. CONCLUSIONS: This study shows that triple @entity7619 -based eradicating regimens are effective and safe. Incidence of side effects seems low and similar in different three-drug regimens used. Quadruple therapy, which appear highly efficacious as a second line therapy, is associated with a significantly higher incidence of side effects when compared to first-line treatment.

Efficacy and tolerability of antibiotics in XXXX undergoing @entity1534 eradication.

@entity1 :: ('9606', 'Species') :: ['patients', 'people'] @entity137 :: ('MESH:D064420', 'Disease') :: ['drug side effects'] @entity115 :: ('MESH:D000658', 'Chemical') :: ['amoxicillin'] @entity7015 :: ('MESH:D014011', 'Chemical') :: ['tinidazole'] @entity4581 :: ('MESH:D017291', 'Chemical') :: ['clarithromycin'] @entity7352 :: ('CHEBI:36928', 'Chemical') :: ['13C'] @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal diseases'] @entity7619 :: ('MESH:C063129', 'Chemical') :: ['rabeprazole'] @entity1535 :: ('MESH:D001729', 'Chemical') :: ['bismuth'] @entity1534 :: ('210', 'Species') :: ['H. pylori', 'Helicobacter pylori'] @entity803 :: ('MESH:D013752', 'Chemical') :: ['tetracycline'] @entity11450 :: ('MESH:C073340', 'Chemical') :: ['ranitidine bismuth citrate']
@entity1 :: (9606,Species) :: ['patients']
